Explore how very high-risk localized prostate cancer is defined and treated, plus why PSMA PET findings shouldn’t automatically rule out curative therapy.
Intensifying Therapy in Very High-Risk Localized Prostate Cancer
Advertisement
Advertisement
Trending on Urology Times
1
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
2
LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC
3
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
4
ESMO 2026 recap: Notable updates across genitourinary oncology
5